These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 19011039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 5. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC.
    Prostate; 2008 Jan 01; 68(1):85-91. PubMed ID: 18008330
    [Abstract] [Full Text] [Related]

  • 8. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 9. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW, Lau KW, Tam PC, Shiu SY.
    Prostate; 2002 Jul 01; 52(2):106-22. PubMed ID: 12111702
    [Abstract] [Full Text] [Related]

  • 10. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 11. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 12. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
    DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC.
    Prostate; 2002 Jul 01; 52(2):123-9. PubMed ID: 12111703
    [Abstract] [Full Text] [Related]

  • 13. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET.
    Cancer Res; 2006 Mar 15; 66(6):3087-95. PubMed ID: 16540658
    [Abstract] [Full Text] [Related]

  • 16. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
    Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB.
    Cancer Res; 2003 Nov 01; 63(21):7365-76. PubMed ID: 14612535
    [Abstract] [Full Text] [Related]

  • 17. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE, Chung LW.
    Prostate; 2007 May 15; 67(7):722-31. PubMed ID: 17342749
    [Abstract] [Full Text] [Related]

  • 18. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

  • 19. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
    Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC.
    Cancer Res; 2007 Jun 15; 67(12):5747-53. PubMed ID: 17575141
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-6 regulation of prostate cancer cell growth.
    Culig Z, Steiner H, Bartsch G, Hobisch A.
    J Cell Biochem; 2005 Jun 01; 95(3):497-505. PubMed ID: 15838876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.